国家乳腺摄影数据库中筛查乳腺摄影召回后诊断性评估与活检的实施率及及时性
该研究基于美国放射学会国家乳腺摄影数据库2008年至2021年的2874310例异常筛查乳腺摄影(BI-RADS 0),回顾性分析诊断性评估与活检的实施率及及时性。异常筛查后随访记录率为66.4%,诊断性评估总体中位时间9天,推荐活检者活检记录率74.8%,诊断性评估至活检总体中位时间21天。年轻、黑人、美洲印第安人及无乳腺癌家族史女性随访率较低,黑人和西班牙裔女性及农村、社区医院附属机构的评估与活检时间较长。
要点
- 异常筛查乳腺摄影后仅66.4%有随访记录,黑人(57.4%)和美洲印第安人(59.5%)女性随访率较低。
- 诊断性评估总体中位时间9天,黑人、其他或混合种族及西班牙裔女性分别为14、14、13天。
- 推荐活检者活检记录率74.8%,美洲印第安人女性仅52.2%;诊断性评估至活检总体中位时间21天。
核心结论
- 异常筛查乳腺摄影后诊断性评估与活检的实施率和及时性存在差异,部分女性亚群和机构可能受益于针对性干预以促进及时诊断解决和活检。
研究设计与样本
- 回顾性识别美国放射学会国家乳腺摄影数据库2008年1月1日至2021年12月31日期间评估为BI-RADS 0的异常筛查乳腺摄影,评估并比较不同患者和机构人口学特征下的诊断性评估与活检实施率及及时性。
诊断标准与关键数值
- 异常筛查乳腺摄影定义为BI-RADS 0评估。
- 2874310例异常筛查乳腺摄影中,66.4%(n=1909326)记录了随访。
- 318977例召回筛查乳腺摄影推荐活检中,238556例(74.8%)记录了活检。
- 诊断性评估总体中位时间9天;诊断性评估至活检总体中位时间21天。
临床应用与阅片要点
- 异常筛查乳腺摄影(BI-RADS 0)后诊断性评估总体中位时间9天,诊断性评估至活检总体中位时间21天。
- 年轻女性(<30岁59.4%、30-39岁63.2%)、黑人(57.4%)、美洲印第安人(59.5%)及无乳腺癌家族史(63.0%)女性随访率较低。
- 黑人(14天)、其他或混合种族(14天)及西班牙裔(13天)女性诊断性评估中位时间较长。
- 老年(≥80岁71.5%)、黑人(71.5%)及美洲印第安人(52.2%)女性活检记录率较低。
- 老年(≥80岁23天)、黑人(25天)、混合或其他种族(26天)、西班牙裔(23天)女性及农村(24天)或社区医院附属机构(22天)活检中位时间较长。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To describe the rate and timeliness of diagnostic resolution after an abnormal screening mammogram in the ACR's National Mammography Database.
METHODS: Abnormal screening mammograms (BI-RADS 0 assessment) in the National Mammography Database from January 1, 2008, to December 31, 2021, were retrospectively identified. The rates and timeliness of follow-up with diagnostic evaluation and biopsy were assessed and compared across patient and facility demographics.
RESULTS: Among the 2,874,310 screening mammograms reported as abnormal, follow-up was documented in 66.4% (n = 1,909,326). Lower follow-up rates were observed in younger women (59.4% in women < 30 years, 63.2% in women 30-39 years), Black (57.4%) and American Indian (59.5%) women, and women with no breast cancer family history (63.0%). The overall median time to diagnostic evaluation was 9 days. Longer median diagnostic evaluation time was noted in Black (14 days), other or mixed race (14 days), and Hispanic women (13 days). Of the 318,977 recalled screening mammograms recommended for biopsy, 238,556 (74.8%) biopsies were documented. Lower biopsy rates were noted in older women (71.5% in women aged ≥80) and Black (71.5%) and American Indian (52.2%) women. The overall median time from diagnostic evaluation to biopsy was 21 days. Longer median biopsy time was noted in older (23 days aged ≥80), Black (25 days), mixed or other race (26 days), and Hispanic women (23 days), and rural (24 days) or community hospital affiliated facilities (22 days).
DISCUSSION: There is variability in the rates and timeliness of diagnostic evaluation and biopsy in women with abnormal screening mammogram. Subsets of women and facilities could benefit from targeted interventions to promote timely diagnostic resolution and biopsy after an abnormal screening mammogram.
引用
- Oluyemi ET, Grimm LJ, Goldman L, et al. Rate and Timeliness of Diagnostic Evaluation and Biopsy After Recall From Screening Mammography in the National Mammography Database. J Am Coll Radiol. 2023. PMID: 37722468. doi:10.1016/j.jacr.2023.09.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。